Take-aways:
1. from the cashflows of 1H22, they paid for the Medlab acquisition in full!
2. from cashflows of 1H22, they paid 55m$ off their borrowings. Now they are net cash as @ 31/12/21!
3. opened a new purpose-built laboratory in Brisbane in November 2021 - which is dedicated to clinical trials - another revenue in future.
4. Will be paying 62m$ for Medlab acquistion rather than 70m$ - and ongoing EBIT form Medlab will be >20m$ by december 2022!
5. Currently looking at few acquisition opportunities in NSW & QLD. And also new revenue models too!! So the acquisitions could be in different field. Maybe in clinical trials, who knows.. but some news will come soon otherwise why would they pay off all their loans?
All in all pretty happy with the results and also the decision of the mgmt to retain most profits in the company rather than paying off excessive dividends.
Ann: Media Release - 1H22 Financial Results, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.42 |
Change
-0.120(3.39%) |
Mkt cap ! $689.6M | |||
| Open | High | Low | Value | Volume |
| $3.52 | $3.54 | $3.29 | $5.882M | 1.723M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3520 | $3.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.42 | 16060 | 4 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ACL (ASX) Chart |